This is a video explaining the request by the Coalition for Affordable T-DM1 to use the Crown Use provisions in the UK patents law, in order to grant compulsory licences on the patents relating to the cancer drug T-DM1, marketed by Roche under the brand name Kadcyla. The video was produced and edited by Zack Struver for KEI, and features narration by Merith Basey from UAEM.
The video will be of interest to anyone interested in efforts to curb high prices for cancer drugs, and of particular interest to HER2+ breast cancer patents, including those living in Scotland, Wales and Northern Ireland, where Kadcyla is not paid for by the NHS, and in England, where the Cancer Drug Fund will de-list Kadcyla in November 2015.